Pfizer (PFE) recently reported a revenue decline tied to weaker COVID product sales and a US$4.4b impairment charge, while ...
Pfizer’s recent positive data for atirmociclib, tilrekimig, Padcev, and the Lyme disease vaccine candidate highlight pipeline ...
AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net ...
Zacks Investment Research on MSN
Pfizer's non-oncology portfolio in focus ahead of Q1 earnings
Pfizer PFE is scheduled to report its first-quarter 2026 results on May 5, with investor focus firmly on its oncology ...
Pfizer Inc. (NYSE:PFE) plays a significant role in global healthcare by supplying medicines and vaccines to healthcare ...
Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...
Obesity is a growing problem that now has effective treatments. Pfizer has been eager to develop a strong position in this area. This acquisition gives Pfizer a viable obesity drug candidate. Pfizer's ...
Pfizer is set to report its first-quarter earnings next month, with analysts expecting profits to decline in the low ...
Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products. The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled ...
Pfizer delivered strong 3Q25 results, beating EPS and revenue estimates, and raised full-year EPS guidance while maintaining robust cost-saving targets. PFE's $10B acquisition of Metsera secures a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results